Search Within

Hematologic Malignancies, Division of

Formats
  1. Meeting Abstract (6372)
  2. Journal Article (5781)
  3. Review (421)
  4. Editorial (196)
  5. Book Section (188)
  6. Research Letter (179)
  7. Guidelines (88)
  8. Conference Paper (65)
  9. Correspondence (62)
  10. Miscellaneous (18)
  11. Book Whole (9)
Groups
  1. Department of Medicine (13278)
  2. Center for Hematologic Malignancies (10612)
  3. GSK Faculty (4482)
  4. Adult Leukemia (3673)
  5. Bone Marrow Transplant (2848)
  6. Lymphoma (2705)

More Groups

People
  1. Sergio Giralt (1069)
  2. Miguel-Angel Perales (943)
  3. Ross Levine (787)
  4. Andrew Zelenetz (784)
  5. Steven Horwitz (669)
  6. Martin Tallman (655)

More People

Years
  1. 2025 (340)
  2. 2024 (823)
  3. 2023 (1038)
  4. 2022 (964)
  5. 2021 (875)
  6. 2020 (936)

More Years

Publications
  1. Blood (3529)
  2. Journal of Clinical Oncology (1233)
  3. Biology of Blood and Marrow Transplantation (596)
  4. Clinical Lymphoma, Myeloma and Leukemia (330)
  5. Haematologica (292)
  6. Bone Marrow Transplantation (239)

More Publications

Publishers
  1. American Society of Hematology (3806)
  2. Elsevier Inc. (1530)
  3. American Society of Clinical Oncology (1288)
  4. Nature Publishing Group (1009)
  5. American Association for Cancer Research (641)
  6. Wiley Blackwell (433)

More Publishers

Results (13379)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Clonal hematopoiesis in survivors of childhood cancer
    Research Letter

    Friedman, D. N.; Chan, I. C. C.; Moskowitz, C. S.; Li, S.; Turner, K.; Liu, J.; Bouvier, N.; Walsh, M. F.; Spitzer, B.; Kung, A. L.; more...
    Blood Advances (2023)

    Fulltext@MSK | Save
  • Critically Ill hematopoietic stem cell transplantation patient: Provider burnout and support
    Book Section

    Sitner, N. C.; Tipian, C. C.; Jakubowski, A. A.; Pastores, S. M.
    In Soubani. A. O. (Eds.) Pulmonary and Critical Care Considerations of Hematopoietic Stem Cell Transplantation (2023)

    Fulltext@MSK | Save
  • Association between non-European ancestry, low socioeconomic status, and receipt of HLA-disparate allografts in adult BMT recipients
    Research Letter

    Fingrut, W. B.; Chinapen, S.; Flynn, J.; Katrichis, A.; Stewart, M.; Davis, E.; Shaffer, B. C.; Shah, G. L.; Barker, J. N.
    Blood Advances (2023)

    Fulltext@MSK | Save
  • Unique genomic alterations and microbial profiles identified in patients with gastric cancer of African, European, and Asian Ancestry: A novel path for precision oncology
    Conference Paper

    Abate, M.; Walch, H.; Arora, K.; Vanderbilt, C. M.; Fei, T.; Drebin, H.; Shimada, S.; Maio, A.; Kemel, Y.; Stadler, Z. K.; more...
    Lippincott Williams & Wilkins (2023)

    Fulltext@MSK | Save
  • A phase II study of palbociclib combined with retifanlimab in patients with advanced dedifferentiated liposarcoma
    Meeting Abstract

    D'Angelo, S. P.; Rosenbaum, E.; Gularte Mérida, R.; Dickson, M. A.; Keohan, M. L.; Gounder, M. M.; Chi, P.; Movva, S.; Kelly, C. M.; Avutu, V.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • A pilot trial of autologous tumor infiltrating lymphocytes (lifileucel, LN-144) for patients with asymptomatic melanoma brain metastases
    Meeting Abstract

    Betof Warner, A.; Postow, M. A.; Panageas, K.; Smithy, J. W.; Schoenfeld, A. J.; Wolchok, J. D.; Shoushtari, A. N.
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • ENVASARC: A pivotal trial of envafolimab and envafolimab in combination with ipilimumab in patients with advanced or metastatic undifferentiated pleomorphic sarcoma or myxofibrosarcoma who have progressed on prior chemotherapy
    Meeting Abstract

    Riedel, R. F.; Chawla, S. P.; Druta, M.; Jones, R. L.s; Schuetze, S.; Lam, J.; Zhuang, D.; Freddo, J. L.; Adams, B. J.; Theuer, C. P.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • A phase 2/3 trial in progress on tebentafusp as monotherapy and in combination with pembrolizumab in HLA-A*02:01+ patients with previously treated advanced non-uveal melanoma (TEBE-AM)
    Meeting Abstract

    Davar, D.; Ikeguchi, A.; Buchbinder, E. I.; Shoushtari, A. N.; Seedor, R. S.; Bernicker, E.; Weiss, S. A.; Daniels, G. A.; Panella, T. J.; Ryan, H. F.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • BRUIN CLL-321: A phase 3 open-label, randomized study of pirtobrutinib versus investigator's choice of idelalisib plus rituximab or bendamustine plus rituximab in BTK inhibitor pretreated chronic lymphocytic leukemia/small lymphocytic lymphoma
    Meeting Abstract

    Follows, G.; Burke, J. M.; Grosicki, S.; Chen, C.; Sanna, A.; Roeker, L. E.; Yi, S.; Munir, T.; de la Cruz, F.; Ferrant, E.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • BRUIN CLL-322: A phase 3 open-label, randomized study of fixed duration pirtobrutinib plus venetoclax and rituximab versus venetoclax and rituximab in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma
    Meeting Abstract

    Eyre, T. A.; Thompson, P.; Wierda, W. G.; Šimkovič, M.; Grosicki, S.; Jurczak, W.; Wang, Y.; Móciková, H.; Zinzani, P. L.; Tam, C. S. L.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save